

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Withdrawn) A process for the preparation of isotonic oil emulsions for intravenous administration, comprising the steps of:
  - providing at least one of estrogens and progestagens;
  - providing an oil phase and an aqueous phase;
  - providing an antioxidant;
  - dissolving the at least one of estrogen and progestagen in the oil phase; and
  - emulsifying the oil phase in the aqueous phase; in the presence of an emulsifier.
  
2. (Currently Amended) A hormone-containing isotonic oil emulsion for intravenous administration comprising:
  - at least one ~~[[of]]~~ progestagens~~[[s]]~~ and at least one estrogen~~[[s]]~~;
  - an oil phase;
  - an antioxidant;
  - an emulsifier; and
  - an aqueous phase;

wherein the at least one ~~of the~~ progestagens~~[[s]]~~ and the at least one estrogen~~[[s]]~~ are dissolved in the oil phase prior to being mixed with the aqueous phase.
  
3. (Currently Amended) The hormone-containing isotonic oil emulsion for intravenous administration according to claim 2, comprising the at least one progestagens~~[[s]]~~ and the at least one estrogen~~[[s]]~~ in a ratio of from 2:1 to 200:1.

**Appln No. 10/561.631**  
**Amdt date November 3, 2010**  
**Reply to Final Office action of September 1, 2010**

4. (Currently Amended) The oil emulsion according to claim 2, characterized in that the emulsion contains from 0.005 to 0.5% by weight of the at least[[an]] one estrogen and from 0.05 to 5% by weight of [[a]]the at least one progestagen, based on the total composition.

5. (Currently Amended) The oil emulsion according to claim 2, characterized in that ~~said~~the at least one estrogen is estradiol and ~~said~~the at least one progestagen is progesterone.

6. (Currently Amended) The oil emulsion according to claim 2, characterized in that said oil phase comprises medium chain triglycerides (MCT) having a chain length of from 6 to 12, ~~preferably from 8 to 10~~, carbon atoms.

7. (Currently Amended) The oil emulsion according to claim 2, characterized by containing [[up]]from 0.6% to 1.5% by weight of the emulsifier, based on the total composition.

8. (Withdrawn) Use of the isotonic oil emulsion according to any of claims 2 to 7 for preparing a medicament for intravenous administration of estrogen and progestagen for postnatal hormone substitution in premature babies.

9. (Withdrawn) Use of the isotonic oil emulsion according to any of claims 2 to 7 for preparing a medicament for the treatment of neurological damage after strokes.

10. (Withdrawn) A process for hormone substitution in premature babies by using the isotonic oil emulsion according to any of claims 2 to 7.

11. (Withdrawn) A process for the treatment of neurological damage after strokes by using the isotonic oil emulsion according to any of claims 2 to 7.

12. (Previously Presented) The hormone-containing isotonic oil emulsion

**Appln No. 10/561.631**  
**Amdt date November 3, 2010**  
**Reply to Final Office action of September 1, 2010**

for intravenous administration according to claim 2; further comprising a co-emulsifier.

13. (Previously Presented) The hormone-containing isotonic oil emulsion for intravenous administration according to claim 12, wherein the co-emulsifier is present in an amount of from 0.005 to 0.1% by weight, based on the total composition.

14. (Previously Presented) The hormone-containing isotonic oil emulsion for intravenous administration according to claim 2; wherein the antioxidant comprises tocopherols or tocopherol esters.

15. (Previously Presented) The hormone-containing isotonic oil emulsion for intravenous administration according to claim 2; wherein the antioxidant is present in an amount from about 10mg to 1000mg, based on 100g of the oil phase.

16. (Previously Presented) The hormone-containing isotonic oil emulsion for intravenous administration according to claim 2; having a pH value from 6.0 to 9.0.